New funding: Just seven months after announcing a $53 million Series A round, Umoja Biopharma has raised an additional $210 million in a Series B round. The company is developing immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. Umoja launched in 2019 and is working to commercialize technology developed at Seattle Children’s Research Institute and Purdue University. The company’s headquarters are in Seattle, and it has a manufacturing operations site in Boulder, Colo. The name comes from a Swahili word for unity.
In this article
No tags related to this article.